Fed Circuit affirms cancellation of Anacor antifungal patents

Anacor Pharmaceuticals has unsuccessfully challenged the invalidation of four patents covering Kerydin (tavaborole), an antifungal treatment for nails.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Genentech to face revived Hemlibra claims

28 August 2020 Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

Americas

Amgen urges Fed Circuit to deny Sandoz petition

27 August 2020 Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.

Americas

Flatwing fails to shift attorney fees to Pfizer unit, Anacor

29 June 2021 Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.

More on this story

Big Pharma

Genentech to face revived Hemlibra claims

28 August 2020 Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

Americas

Amgen urges Fed Circuit to deny Sandoz petition

27 August 2020 Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.

Americas

Flatwing fails to shift attorney fees to Pfizer unit, Anacor

More on this story

Big Pharma

Genentech to face revived Hemlibra claims

28 August 2020 Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

Americas

Amgen urges Fed Circuit to deny Sandoz petition

27 August 2020 Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.

Americas

Flatwing fails to shift attorney fees to Pfizer unit, Anacor